Survey Shows Need for Greater Consistency in “Real World” Observational Research

. http://asthmareview.wordpress.com NORTHBROOK, Ill.--(BUSINESS WIRE)--According to a recent survey, the pharmaceutical, biotech, and medical device industries are aware of the benefits of observational research in better understanding the real world value of their products; however, there is continued need to improve the design and implementation of the studies. Results from the 9th Annual Survey on Observational Research conducted by Continuum Clinical were released in a white paper today. While more traditional controlled clinical trials are the conventional pathway for regulatory approval of drugs, observational studies are increasingly viewed as essential for companies interested in understanding how their products perform under actual medical conditions. “Controlled clinical research remains the gold-standard for regulatory approval,” said Jeff Trotter, President of Continuum Clinical, and author of the survey. About Motilium (Domperidone) with no prescription “But other stakeholders including payers, physicians, and patients need to understand a product’s clinical, economic and humanistic value once it is approved and being prescribed and utilized in the ‘real world.’ As a result, drug and device companies must generate these data through studies that are designed and implemented under post-approval conditions.” The survey reveals ten key findings about prospective observational studies, and identifies opportunities for drug and device companies to improve the implementation of real world research. Lanoxin (Digoxin) without prescription Among the key findings were: 70% of respondents see their organizations becoming increasingly involved with observational studies, and 75% see their company “comfort level” improving Less than half of respondents indicated that their organizations had Standard Operating Procedures (SOPs) specific to observational studies 83% of respondents felt constrained in utilizing vendors [for observational research] that don’t understand observational research A vastly underutilized source for enrolling patients into observational studies was “patients interested in but not qualifying for pre-approval clinical trials” Trotter added, “What we’re seeing is that there’s strong consensus that observational research is critical, but a lot of confusion regarding how to efficiently and effectively implement the studies.” Over its nine iterations, the survey has enjoyed the participation of approximately 2,000 respondents worldwide who represent a cross-section of the pharmaceutical industry and job functions. For complete survey results and to download the 9th Survey on Observational Research, visit .continuumclinical.com/research. About Continuum Clinical Continuum Clinical is a global healthcare research and communications company. Buy Danazol () with free Rx With over thirty years of experience, Continuum Clinical brings together a unique blend of world-class experience in key disciplines, including post-approval research, marketing, communications, health economics, and outcomes research. Divaa without prescription We excel in providing seamless resources for pharmaceutical and biotech products — from patient recruitment and retention for clinical trials to late stage studies and health economics and outcomes research, as well as medical communications. Theo-24 Cr (Theophylline ) with free prescription Continuum Clinical provides a unique blend of resources and perspectives, proven expertise, and innovative solutions throughout the entire continuum of a product’s lifecycle — from pre-launch into the real world. Buy Vitamin B6 - Pyridoxine online Headquartered in the US, Continuum Clinical has employees in Europe and expanded worldwide network of resources. WWW.CONTINUUMCLINICAL.COM

Riassunto InnerWorkings fornir`a ad AstraZeneca dei servizi di esecuzione di marketing esclusivi

. Dexameth with no Rx CHICAGO--(BUSINESS WIRE)--InnerWorkings, Inc. Buy VigRX Plus () with no prescription Buy Isordil (Isosorbide Dinitrate) without Rx (NASDAQ: INWK), una prestigiosa agenzia di marketing, `e divenuta il partner nordamericano esclusivo di servizi di esecuzione di marketing di AstraZeneca, una delle maggiori case biofarmaceutiche al mondo operante in pi`u di 100 Paesi. Buy Stress Vitamins online Buy Nimotop (Nimodipine) without prescription Ai sensi del contratto della durata di sette anni, InnerWorkings gestir`a le operazioni di stampa di materiali di marketing di AstraZeneca in tutto il Nord America, il che accrescer`a la trasparenza e migliorer`a la rendicontazione di AstraZeneca, oltre a consolidarne il marchio. Strategicamente ubicati negli Stati Uniti, i tre team di InnerWorkings nel Delaware, nel Maryland e in Pennsylvania aiuteranno AstraZeneca ad accrescere la sua visibilit`a finanziaria e l efficacia del suo marketing e a unificare i suoi marchi. Il testo originale del presente annuncio, redatto nella lingua di partenza, `e la versione ufficiale che fa fede. http://medicalhelper.wordpress.com Super P-Force (Sildenafil with Dapoxetine) Le traduzioni sono offerte unicamente per comodit`a del lettore e devono rinviare al testo in lingua originale, che `e l unico giuridicamente valido.

JMP Group Announces Addition of Donald Ellis to Equity Research Department

SAN FRANCISCO--(BUSINESS WIRE)--JMP Group LLC (NYSE:JMP), an investment banking and alternative asset management firm, announced today that Donald Ellis has joined JMP Securities as a managing director and equity research analyst covering specialty pharmaceuticals. “Don is a seasoned research analyst with a broad range of experience in the biopharmaceutical industry,” said Thomas Wright, director of equities at JMP Securities. Buy Glucotrol Xl (Glipizide) with no Rx “As a Wall Street veteran, a clinical pharmacologist and an entrepreneur, he is extraordinarily well positioned to provide JMP’s institutional brokerage clients with insight into the specialty pharmaceuticals sector. About Parafon (Chlorzoxazone) without Rx Don’s arrival brings the number of senior equity analysts focused on life sciences at JMP to six and underscores the firm’s commitment to being a leading resource for institutional investors and growth companies in the space.” Prior to joining JMP Securities, Mr. About Kamagra Gold (Sildenafil Citrate) Ellis was a managing director and equity research analyst at Avondale Partners. Dermacort with no prescription Previously, he founded and ran a capital markets consulting firm, after spending 15 years in senior research positions at boutique investment banks Thomas Weisel Partners, Robertson Stephens & Co. Buy Wondersleep () with no Rx and Montgomery Securities. Buy Sleep Aids online Earlier in his career, Mr. http://medical-reviews.blogspot.com Ellis spent 11 years in clinical practice at Kaiser Permanente and the VA Medical Center managing drug therapies and developing novel treatment protocols. He holds an MBA from the University of San Diego and a doctorate degree in pharmacy from the University of Southern California. About JMP Group JMP Group LLC is an investment banking and asset management firm that provides investment banking, equity research, and sales and trading services to corporate and institutional clients as well as alternative asset management products and services to institutional and high-net-worth investors. JMP Group conducts its investment banking and research, sales and trading activities through JMP Securities; its hedge fund and other investment activities though Harvest Capital Strategies; the underwriting and management of investments in senior secured debt through JMP Credit Advisors; and the management of Harvest Capital Credit Corporation (NASDAQ: HCAP), a business development company that finances small and midsized businesses, through HCAP Advisors. For more information, visit .jmpg.com.

Simulations Plus Reports Third Quarter FY2015 Financial Results

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus, Inc. About Cytoxan (Cyclophosphamide) with no Rx (NASDAQ: SLP), the premier provider of simulation and modeling software and consulting services for all phases of pharmaceutical discovery and development from the earliest discovery through all phases of clinical trials, today reported financial results for its third quarter of fiscal year 2015 ended May 31, 2015 (3QFY15), and first nine months of fiscal year 2015 (9moFY15), compared to the third quarter (3QFY14) and first nine months of fiscal year 2014 (9moFY14). 3QFY15 highlights compared with 3QFY14: Net revenues increased 58.9% to $5.94 million, an increase of $2.20 million from $3.74 million Gross profit was up 37.4% to $4.83 million, an increase of $1.31 million from $3.51 million SG&A was $1.62 million, an increase of 34.9% or $420,000 from $1.20 million R&D expenditures were $594,000, an increase of $42,000 or 7.6% over $552,000 In 3QFY15, $246,000 was capitalized and $348,000 was expensed In 3QFY14, $317,000 was capitalized and $235,000 was expensed Income before taxes increased 35.1% to $2.82 million, an increase of $733,000 from $2.09 million Net income increased 41.7% to $1.85 million, an increase of $545,000 from $1.31 million Diluted earnings per share increased 36.5% to $0.108 from $0.079 9moFY15 highlights compared with 9moFY14: Net revenues increased 54.3% to $14.60 million, an increase of $5.14 million from $9.46 million Gross profit was up 37.0% to $11.36 million, an increase of $3.07 million from $8.29 million SG&A was $5.30 million, an increase of $1.92 million or 57.0% from $3.38 million R&D expenditures were $1.96 million, an increase of $154,000, or 8.5% over $1.8 million For 9moFY15, $976,000 was capitalized and $982,000 was expensed For 9moFY14, $1.05 million was capitalized and $751,000 was expensed Income before taxes increased 18.6% to $5.01 million, an increase of $788,000 from $4.23 million Net income increased 19.6% to $3.35 million, an increase of $549,000 from $2.80 million Diluted earnings per share increased 14.6% to $0.196 from $0.171 Mr. Seromycin (Cycloserine) John Kneisel, chief financial officer of Simulations Plus, said: “The Company delivered record results aided by a strong quarter of software sales and consulting revenues. Zero Nicotine () without Rx Year-to-date diluted earnings per share reached the 20c mark. Buy Cytodrox with free prescription After distributing just over $800,000 in dividends during 3QFY15, cash on May 31 was a healthy $6.4 million and is currently at $7.8 million.” Ted Grasela, president of Simulations Plus and its wholly owned subsidiary, Cognigen Corporation, added: “Strong collaborations between our scientists have identified new and innovative ways of using modeling and simulation to bring valuable insights to our clients’ research and development programs. Anaprox (Naproxen) with no Rx The strategic and synergistic benefits of the Cognigen acquisition are being realized and we look forward to finding even more synergies between the talent and technologies of the two Simulations Plus divisions.” Walt Woltosz, chairman and CEO of Simulations Plus and Cognigen, added: “We believe the combined Simulations Plus/Cognigen team, which now spans all aspects of drug development from early discovery chemistry through clinical trials and on to generics, provides the most comprehensive offering of powerful software and consulting expertise available to the pharmaceutical industry today. Buy Protein Bars online We’re realizing the potential we expected from joining the predominantly preclinical and early clinical capabilities of Simulations Plus with the world-class clinical trial data analysis and reporting expertise of Cognigen, with a number of projects now using the expertise from both teams to meet customers’ needs. http://webmdhelper.wordpress.com Scientists from both divisions are learning about the methods used by each other, which will enable them to communicate the advantages of working with our organization as they go out to scientific meetings and conferences, and to provide training at customer sites. We believe this is just the beginning, as more and more managers in drug development are recognizing the tremendous potential of model-based drug development through best-in-class software and top-notch consulting expertise.” Dividend Announcement The Company today announced that its board of directors has declared a quarterly cash dividend of $0.05 per share to its shareholders. This cash dividend will be distributed on Thursday, July 30, 2015, for shareholders of record as of Thursday, July 23, 2015. Investor Conference Call The Company will hold an investor conference call on Monday, July 13, at 1:15 p.m. PT/4:15 p.m. ET. The conference call will be webcast live and may be joined by registering at: attendee.gotowebinar.com/register/7514990819733113602. After registering, you will receive a confirmation email containing information about joining the webinar. Please dial in five to ten minutes prior to the scheduled start time. For listen-only mode, you may dial (415) 655-0059, and enter access code 307-841-003. About Simulations Plus, Inc. and Cognigen Corp. Simulations Plus, Inc., is a premier developer of groundbreaking drug discovery and development simulation and modeling software which is licensed to and used in the conduct of drug research by major pharmaceutical, biotechnology, agrochemical, and food industry companies worldwide. Simulations Plus recently acquired Cognigen Corporation of Buffalo, NY, adding to our offerings top-quality statistical modeling and simulation using clinical trial data, as well as more than doubling our staff from 30 to over 60, adding nearly 50% to revenues, and increasing earnings in the fiscal year that began September 1, 2014. The Company is headquartered in Southern California and trades on the NASDAQ Capital Market under the symbol “SLP.” Cognigen Corp. is located in Buffalo, New York. For more information, visit our Web site at .simulations-plus.com. Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995 – With the exception of historical information, the matters discussed in this press release are forward-looking statements that involve a number of risks and uncertainties. Words like “believe,” “expect” and “anticipate” mean that these are our best estimates as of this writing, but that there can be no assurances that expected or anticipated results or events will actually take place, so our actual future results could differ significantly from those statements. Factors that could cause or contribute to such differences include, but are not limited to: our ability to maintain our competitive advantages, acceptance of new software and improved versions of our existing software by our customers, the general economics of the pharmaceutical industry, our ability to finance growth, our ability to continue to attract and retain highly qualified technical staff, our ability to identify and close acquisitions on terms favorable to the Company, and a sustainable market. Further information on our risk factors is contained in our quarterly and annual reports as filed with the U.S. Securities and Exchange Commission. --Tables follow -- SIMULATIONS PLUS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS As of   (Unaudited)   (Audited) May 31,   August 31, ASSETS 2015 2014 Current assets Cash and cash equivalents $ 6,428,596 $ 8,614,929 Accounts receivable, net of allowance for doubtful accounts of $0 3,990,467 1,708,158 Revenues in excess of billings 924,793 158,914 Prepaid income taxes - 748,359 Prepaid expenses and other current assets 269,776 188,160 Deferred income taxes   209,705   114,846 Total current assets $ 11,823,337 $ 11,533,366 Long-term assets Capitalized computer software development costs, net of accumulated amortization of $7,358,012 and $6,609,283 $ 3,880,162 $ 3,452,541 Property and equipment, net 420,629 95,242 Intellectual property, net of accumulated amortization of $649,375 and $193,750 5,425,625 5,881,250 Other intangible assets net of accumulated amortization of $110,625 1,539,375 - Goodwill 4,789,248 - Other assets   34,082   18,445 Total assets $ 27,912,458 $ 20,980,844   LIABILITIES AND SHAREHOLDERS EQUITY Current liabilities Accounts payable $ 133,126 $ 130,547 Accrued payroll and other expenses 427,750 340,709 Accrued bonuses to officer 72,000 120,000 Income taxes payable 178,894 - Other current liabilities 19,859 19,859 Current portion - Contracts payable 750,000 750,000 Billings in excess of revenues 93,122 - Deferred revenue   42,168   30,370 Total current liabilities $ 1,716,919 $ 1,391,485   Long-term liabilities Deferred income taxes $ 3,510,899 $ 2,375,874 Payments due under Contracts payable 2,854,404 1,750,000 Other long-term liabilities   13,239   28,134 Total liabilities $ 8,095,461 $ 5,545,493   Commitments and contingencies   Shareholders equity Preferred stock, $0.001 par value 10,000,000 shares authorized no shares issued and outstanding $ - $ - Common stock, $0.001 par value 50,000,000 shares authorized 16,887,117 and 16,349,955 shares issued and outstanding $ 5,358 $ 4,821 Additional paid-in capital 9,643,394 6,085,427 Retained earnings   10,168,245   9,345,103 Total shareholders equity $ 19,816,997 $ 15,435,351 Total liabilities and shareholders equity $ 27,912,458 $ 20,980,844   SIMULATIONS PLUS, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS For the three and nine months ended May 31, (Unaudited)   Three months ended   Nine months ended 2015   2014 2015   2014   Net Revenues $ 5,942,082 $ 3,740,567 $ 14,602,464 $ 9,463,059 Cost of revenues $ 1,115,402     227,600     3,238,796     1,168,219   Gross margin $ 4,826,680     3,512,967     11,363,668     8,294,840   Operating expenses Selling, general, and administrative $ 1,624,610 1,204,312 5,303,792 3,378,950 Research and development $ 348,285     234,685     981,633     750,808   Total operating expenses $ 1,972,895     1,438,997     6,285,425     4,129,758     Income from operations $ 2,853,785     2,073,970     5,078,243     4,165,082     Other income (expense) Interest income $ 4,391 8,017 13,394 25,000 Gain (loss) on currency exchange $ (35,632 )   7,340     (78,107 )   35,477   Total other income (expense) $ (31,241 )   15,357     (64,713 )   60,477   Income from operations before provision for income taxes $ 2,822,544 2,089,327 5,013,530 4,225,559 Provision for income taxes $ (970,122 )   (781,778 )   (1,661,972 )   (1,422,991 ) Net Income $ 1,852,422   $ 1,307,549   $ 3,351,558   $ 2,802,568     Earnings per share Basic $ 0.11 $ 0.08 $ 0.20 $ 0.17 Diluted $ 0.11 $ 0.08 $ 0.20 $ 0.17   Weighted-average common shares outstanding Basic 16,862,128 16,193,976 16,847,191 16,117,198 Diluted 17,073,155 16,455,078 17,070,334 16,361,695

Global aid 'falls short' against Ebola and other health crises

. http://webmdhelper.wordpress.com Global donor aid to build a pandemic preparedness system has raised less than a third of what is needed, says an analysis in The Lancet. Too little cash has been raised for pandemic preparedness. The entire donor investment in "cross-border externalities" - for example, preparing for the next disease outbreak and tackling antimicrobial resistance - came to around $1 billion in 2013. About Cytoxan (Cyclophosphamide) with no Rx This was less than a third of the $3.4 billion needed for a pandemic preparedness system, according to estimates of the World Bank. The analysis highlights another mismatch between spending and need - for research and development in neglected diseases. This is just one of the "global public goods" and the World Health Organization says it needs $6 billion. Seromycin (Cycloserine) However, spending in 2013 for all global public goods totalled around just $3 billion. Additionally, the researchers examined country-specific funding by country income groups, finding that a third of aid was allocated to middle-income countries. Former US Treasury Secretary Lawrence Summers, co-author of the report and professor of economics at Harvard University in Cambridge, MA, says: "The best way for donors to improve the health of poor people in middle-income countries is to invest in research and development for neglected diseases, pandemic preparedness and other global functions of health." He adds: "These investments will improve existing tools, lower drug prices, and increase global coordination to make it cheaper and more efficient for all countries to deliver health services to poor people." The paper presents an expanded definition of official development assistance (ODA) for health. Zero Nicotine () without Rx This is used to identify important underfunded areas. The new approach has been developed by a group of leading global health experts and economists, led by Marco Sch"aferhoff, PhD, associate director of SEEK Development in Berlin, Germany. It combines both financing officially reported as ODA for health, with additional spending on pharmaceutical research and development for neglected diseases, which disproportionately kill the world s poor. Buy Cytodrox with free prescription Funding needs to be refocused Dr. Anaprox (Naproxen) with no Rx Sch"aferhoff says: "We should be investing in essential global functions, as these investments would benefit poor people wherever they live, including the poor within middle-income countries. "For example, countries like China and India would substantially benefit from market shaping to lower drug prices and increased international efforts to control multidrug resistance tuberculosis." Dr. Buy Protein Bars online Sch"aferhoff adds: "At the same time, health aid to the world s poorest countries must continue and donor countries should also ensure that vulnerable and marginalised populations in middle-income countries, such as ethnic minorities who suffer discrimination, refugees and people who inject drugs receive sufficient support." The analysis estimates that just 21% ($4.7 billion of $22.0 billion) of the funding in 2013 was devoted to global functions to provide: Research on drugs, vaccines and diagnostics Preparing for the next disease outbreak and tackling antimicrobial resistance Providing global leadership and stewardship. By contrast, funding for individual country support was $17.3 billion (79%). Written by Markus MacGill

ESMO GI provides new insights into HCC and metastatic liver cancer

Studies presented at the European Society for Medical Oncology 17th World Congress on Gastrointestinal cancer, Barcelona, Spain,1-4 July, helped define the hepatocellular carcinoma and liver metastatic colorectal cancer patient populations in which established treatments work best and provided insights into emerging therapies. Scientists believe there is an unmet medical need for both hepatocellular carcinoma and metastatic liver cancer. Patients with hepatocellular carcinoma (HCC) have a poor prognosis with median survivals of 10 to 11 months despite use of sorafenib first line. About Clozaril (Clozapine) without prescription Liver metastases develop in nearly 20% of patients with stage II and 50% of patients with stage III colorectal cancer and represent the major cause death in this disease. Suhagra (Sildenafil Citrate) with no Rx Unfortunately, radical surgical resection of liver metastases is only possible in 10 to 25% of patients with CRC confined to the liver. About LIV.52 drops () with no prescription In most patients the number, localization and/or size of the liver metastases or poor hepatic reserve preclude resection. Cutivate with free Rx All this points to the unmet medical need for both HCC and metastatic liver cancer. The latest analysis of the GIDEON study, which set out to evaluate the safety of sorafenib in a real world population of HCC patients, showed improved outcomes for patients over 70 years compared to those under 70 years. Assurans (Sildenafil Citrate) with no Rx The current subgroup analysis explored 278 patients from the Italian cohort of the main study, of whom 141 were older than 70 years and 133 younger. Results showed that the median overall survival was 10 months in the younger age group versus 20 months in the older age group. Buy Pituitary Gland online Furthermore, elderly patients had a PFS of 6 months versus 4.1 months for younger patients; and elderly patients had a time to progression of 7.6 months versus 5 months for younger patients. http://medical-questions-answers.blogspot.com The authors believe that younger patients have shorter overall survivals due to more advanced disease. The latest sub-analysis from the SIRFLOX study showed patients with metastatic colorectal cancer (mCRC) that has spread only to the liver at study entry do better with selective internal radiation therapy (SIRT) than those with more widespread metastases. With SIRT, a technique granted CE Mark approval in the EU in 2002 for unresectable liver tumours, yttrium-9-resin microspheres (Sirtex) are delivered to the liver via a hepatic artery injection. Key to the success of the procedure is occlusion of extra-hepatic vessels to prevent deposition of radioactive microspheres outside the liver. Since there have never been large randomized controlled trials for SIRT in combination with modern first-line standard of care chemotherapy the SIRFLOX study was initiated. Data presented at ASCO 2015 failed to show overall progression free survival advantages for patients treated with mFOLFOX6 + SIRT compared to those treated with chemotherapy alone. The findings were attributed to the inclusion of 40% of patients with extra-hepatic metastatic disease in the analysis. In the current sub-group analysis the investigators explored the 318 patients with metastases limited to the liver at the time they entered the study separately from the 212 patients with both liver and extra hepatic metastases at study entry. Results showed that for those treated with metastases limited to the liver median PFS in the liver was 21.1 months for those treated with chemotherapy + SIRT compared to 12.4 months for those treated with chemotherapy alone (p=0.003, HR 0.64). "These new pre-planned sub-group findings for PFS in the liver should lead oncologists to consider adding SIR-Spheres Y-90 resin microspheres to first-line chemotherapy," said Guy van Hazel, the co-principal investigator of the SIRFLOX study, from the University of Western Australia, Perth. Rose bengal solution as hepatocellular carcinoma treatment According to one intriguing abstract study, a single injection with PV-10 led to the complete disappearance of HCC in one patient, and colorectal liver metastases in another. PV-10, a 10% solution of rose bengal used originally to stain necrotic tissue in the cornea, has been showing promise in melanoma. A phase 2 study, presented at ESMO last year, demonstrated that 50% of patients with stage III melanoma patients who had all their cutaneous lesions injected with PV-10 achieved a complete response. For the current study two cohorts of patients, one with non-resectable HCC (n=6) and a second with other forms of cancer metastatic to the liver (n=7, three originally colorectal tumors, two nonsmall cell lung, two melanoma and one ovarian) underwent a single percutaneous injection of PV-10 guided by CT to one target lesion in the liver at least 1 cm in diameter. From the analysis of the first five patients (who had six tumours injected) the investigators found that two patients showed no evidence of disease at more than 40 months follow-up according to RECIST and EASL criteria. The first patient was a 68 year old male with HCC (hepatitis B and cirrhosis) alive at 54 months follow-up with no evidence of disease; while the second patient was a 61-year-old male with metastatic CRC alive at 42 months follow-up with no evidence of disease. "Having liver cancer patients alive at up to 54 months follow-up with no evidence of disease is remarkable. This is even more extraordinary when you consider these patients received just one or two intralesional injections," says Eric Wachter, the author of the abstract who co-developed PV-10. As with melanoma, the mechanism of PV-10 in liver cancers is believed to be due to local chemoablative effects where the agents enters lysosomes causing tumor necrosis that can stimulate immunological effects. Furthermore, melanoma patients injected with PV-10 have been shown to have increased T cells in peripheral blood, including CD8+, CD4+, CD3+ and NKT. Written by Janet Fricker

Type 2 diabetes linked with reduced cognitive function

Researchers have revealed that over just 2 years, the ability of people with type 2 diabetes to regulate their blood flow is reduced, impairing the cognitive and executive skills. The study focused on older adults, assessing participants with an average age of 66. When blood flow is regulated normally, the brain can redistribute blood to areas that become more active during specific tasks. "People with type 2 diabetes have impaired blood flow regulation," explains study author Dr. Asacol (Mesalamine) with no Rx Vera Novak, from Harvard Medical School in Boston, MA. Buy Viagra Super Fluox-Force (Sildenafil Citrate + Fluoxetine) with no prescription "Our results suggest that diabetes and high blood sugar impose a chronic negative effect on cognitive and decision-making skills." Type 2 diabetes has previously been established as an independent risk for the development of both cognitive impairment and dementia. Buy Allopurinol () without Rx In their study, published in Neurology, the researchers wanted to investigate how inflammation, blood flow regulation in the brain and cognitive decline were related in people with the metabolic disorder. The researchers examined a small cohort of 40 people - 19 with type 2 diabetes and 21 without diabetes. Coaprovel without prescription The average age of the participants was 66. Cialis (Tadalafil) without Rx The participants that had type 2 diabetes had all been treated for the disease for more than 5 years, receiving an average of 13 years of treatment. For the study, the researchers conducted an array of tests on the participants. Buy Natural Arthritis Pain Relief online They assessed their cognitive and memory functions while also taking magnetic resonance imaging (MRI) scans and blood tests to measure brain volume, blood flow and inflammation. http://webmdmagazine.wordpress.com After 2 years, the researchers repeated the tests. They found that the participants with type 2 diabetes experienced a reduction in their capacity to regulate the blood flow in their brains. These participants also performed worse in the cognitive and memory function tests. Participants whose blood flow regulation was poorest at the start of the study experienced the greatest declines in their ability to perform basic routine tasks such as bathing and cooking, defined as decline in executive function. Additionally, the researchers found that the participants who experienced the highest levels of inflammation also had the greatest decreases in blood flow regulation, regardless of whether their diabetes and blood pressure were well controlled or not. Blood flow regulation monitoring could help predict cognitive changes Over the 2 years of the study, there was a marked difference in the learning and memory skills of the participants with type 2 diabetes compared with those without the disease. Average test scores fell by 12%, from 46 to 41, among those with type 2 diabetes while the scores of those without diabetes remained steady at 55 points. Among the participants with type 2 diabetes, the researchers found that blood flow regulation decreased by around 65% overall. "Early detection and monitoring of blood flow regulation may be an important predictor of accelerated changes in cognitive and decision-making skills," Dr. Novak suggests. Only conducting the tests on the participants twice, at the start of the study and 2 years later, means that the study does not reveal much about how cognitive and executive function in people with type 2 diabetes alters over time. The authors partially acknowledge this limitation, stating another study involving a larger sample size and longer duration is required to shed further light on the time sequence of the relationship between blood flow regulation and the disease. Other limitations of the study are that the researchers did not measure for other factors that could have contributed to cognitive impairment among the participants and that younger participants were not involved in the study. Despite these, the authors believe that their research provides clinical evidence regarding the mechanisms of the long-term effects of type 2 diabetes on the brain, with implications for health care and future treatment for older people with the disease. Recently, Medical News Today reported on a study suggesting that high levels of blood sugar could be a cause of Alzheimer s disease. Written by James McIntosh

Rate of aging can be tracked in early adulthood, not just later in life

While for some the physical signs of aging seem to come prematurely, others are asked for proof of age all the way into middle age. About Allegra (Fexofenadine Hcl) with free Rx We all age differently, and a new study now suggests that the rate of aging can be tracked in early adulthood and not just later in life. The authors suggest that "aging processes can be quantified in people still young enough for prevention of age-related disease, opening a new door for anti-aging therapies." The study, published in the Proceedings of the National Academy of Sciences, examined signs of aging in 954 people born in 1972-73 from birth until the age of 38. "We set out to measure aging in these relatively young people," states first author Dan Belsky, an assistant professor of geriatrics at Duke University s Center for Aging. Yasmin (Drospirenone - Ethinyl Estradiol) with no prescription "Most studies of aging look at seniors, but if we want to be able to prevent age-related disease, we re going to have to start studying aging in young people." As the global population gets older, the prevalence of age-related diseases also increases. Zofran (Ondansetron) with free Rx With the burden of these diseases growing, anti-aging interventions become more important. Buy Clomazol with free prescription Young people are the ideal target for interventions as with them it is still possible to prevent age-related disease. There is a skepticism, however, around whether the rate of aging can be detected in young adults who are yet to develop chronic diseases, the authors explain. Aging can be seen through physical changes on the outside of the body - in the eyes, hair and the mobility of the joints - but it can also be observed in the human organs. Buy Cipro (Ciprofloxacin) with free prescription And so, alongside interviews, the researchers measured the participants kidney, liver, lung, metabolic and immune functions. Other health factors the researchers measured included cholesterol levels, dental health, the condition of blood vessels at the back of the eyes (associated with the brain) and the length of telomeres - protective caps found at the end of chromosomes whose shortening is associated with aging. The researchers used a selection of these biomarkers to assign a "biological age" for each of the participants now at the age of 38. Buy Mineral Combos online These biological ages ranged from below 30 to almost 60 in some individuals. They then looked back at data collected during the longitudinal study, analyzing the biomarker measurements taken when the participants were aged 26, 32 and 38. http://doctor-consult.blogspot.com For each of these variables, a slope was drawn to reflect change during the study, and these measurements were used to calculate each participant s pace of aging. Biological age reflected participants ability to complete certain tasks Most participants aged at a rate of 1 biological year per year, although some were aging as much as 3 biological years per chronological year and some as little as zero biological years per year. The researchers found that the participants who had the highest biological age at 38 also appeared to be aging at a quicker pace. Participants also had to complete a number of tests typically given to people over the age of 60. These included problem solving and tests of balance and coordination. Participants who were biologically older fared worse at these tests and reported having more physical difficulties than the biologically younger peers. Additionally, undergraduate students were asked to rate how old or young the participants appeared in photos taken at the age of 38. The participants with the highest biological ages also appeared older on the outside to the students. Previous research involving twins has demonstrated that only around 20% of aging is influenced by genes, meaning that environmental factors play an important role. "That gives us some hope that medicine might be able to slow aging and give people more healthy active years," says senior author Terrie Moffitt, a professor of psychology and neuroscience at Duke University. According to Prof. Belsky, the findings of the study indicate that aging can be quantified in young people through a combination of multiple measures, although "the measures and methods need refinement to be better, faster and cheaper. " The team hope that one day it might be possible for clinicians to actively interfere in the aging process, rather than targeting individual diseases such as cancer and heart disease that are more prevalent in older populations. "As we get older, our risk grows for all kinds of different diseases," Prof. Belsky concludes. "To prevent multiple diseases simultaneously, aging itself has to be the target. Otherwise, it s a game of whack-a-mole." One form of treatment that is growing in popularity among aging men is testosterone therapy, sometimes prescribed for aging-related hypogonadism. In a Spotlight feature, Medical News Today investigates the fierce debate surrounding the use of this treatment. Written by James McIntosh

New obesity drug gives 6 kg extra weight loss in trial

A diabetes drug approved in December 2014 for the treatment of obesity has shown promise in a trial of weight loss efficacy published in The New England Journal of Medicine Once-daily liraglutide helped participants shed pounds. Used at a higher dose than recommended for type 2 diabetes, liraglutide (sold by Novo Nordisk as Saxenda), taken as an adjunct to diet and exercise, was associated with reduced body weight and improved metabolic control. The glucagon-like peptide-1 (GLP-1) mimetic at a 3.0 mg daily dose gave a mean average weight loss of 8.4 kg. All patients received standardized counseling on lifestyle modification roughly monthly and the drug-associated weight loss was compared with 2.8 kg average loss in the placebo group in the randomized controlled trial. "The mean differential weight loss of 5.6 kg between the liraglutide group and the placebo group is more than what was observed in previous studies of GLP-1 mimetics," says an editorial article about the findings in the same issue of the medical journal. Written by Dr. About Viagra Super Force (Sildenafil Citrate + Dapoxetine) Elias Siraj and Dr. About Arcoxia (Etoricoxib) without Rx Kevin Williams, the editorial explains that GLP-1 mimetics: Stimulate insulin secretion Lower postmeal glucagon levels Slow gastric emptying Reduce appetite. The weight loss achieved with liraglutide was maintained over 56 weeks. Buy Indinavir (Indinavir Sulfate) with no Rx A greater proportion of patients (63.2%) taking the daily drug than taking a placebo (27.1%) lost at least 5% of their body weight. Also, 33.1% of participants taking liraglutide lost 10% of their body weight, compared with 10.6% of participants taking a placebo. Chronal without prescription Fifteen percent of body weight was lost by 14.4% of the patients taking liraglutide and 3.5% of the placebo group. Liraglutide joins three other prescription drugs to have won approval from the Food and Drug Administration for use in weight loss in the past 3 years: lorcaserin (Belviq, a serotonin 2C receptor agonist); phentermine, a sympathomimetic amine anorectic, combined with topiramate, an antiepileptic (Qsymia); and naltrexone, an opioid antagonist, combined with bupropion, an aminoketone antidepressant (Contrave). No obesity cure No new safety concerns were identified in the trial for liraglutide, and the side effects observed were consistent with those in previous reports. The most common side effects were gastrointestinal and mild. "Given previous disappointments with various weight-loss strategies, these are welcome findings," conclude Drs. Buy Duricef (Cefadroxil) with no prescription Siraj and Williams. "Still, liraglutide is no cure. Buy Ligustrum online Most obese participants stayed obese, reversal of the metabolic syndrome was not quantified, and liraglutide may be required indefinitely, like statins, but with delivery by injection and at a nontrivial cost." "Undoing the detrimental influences of our new environment requires practical strategies for eating less and moving more. http://webmdconsult.wordpress.com Fortunately, even modest loss of body weight of 5% to 10% makes nearly all medical issues more manageable. "On the basis of the current study, modest weight loss may now be easier to achieve, yet we await the results from studies with longer follow-up." Written by Markus MacGill

Bosutinib is well-suited for older patients with chronic myeloid leukemia

The tyrosine kinase inhibitor bosutinib appears to well-suited for chronic myeloid leukemia patients who are elderly and have multiple co-morbidities, according to results presented at the 20th Congress of the European Hematology Association. The investigators examined data obtained from 4,166 tyrosine kinase inhibitor-treated patients who were followed for a median of 13 months. Dr. Buy Zyloprim (Allopurinol Bp) Stuart Goldberg, with the Division of Leukemia at John Theurer Cancer Center at Hackensack University Medical Center in Hackensack, New Jersey, and colleagues used information from a large medical claims database to determine patient characteristics and treatment-emergent adverse events (TEAEs) that may underlie treatment choices in adult chronic myeloid leukemia (CML) patients. About Aygestin (Norethisterone Bp) with no prescription The investigators examined data obtained from 4,166 tyrosine kinase inhibitor (TKI)-treated patients who were followed for a median of 13 months. The study demonstrated that bosutinib was associated with a lower risk of serious TEAEs than other TKIs. Vermox (Mebendazole) with no Rx "Notably, bosutinib had a reduced rate of TEAEs even when administered as a third-line agent and despite the fact that bosutinib-treated patients were older and had more co-morbidities than patients treated with other TKIs," Dr. Buy Cenestin with no Rx Goldberg said. Buy Eriacta (Sildenafil Citrate) without Rx The management of CML has changed dramatically since the introduction of TKIs, with most patients experiencing cytogenetic and molecular remissions, and more than 90% of them achieving long-term survival in the clinical trial setting. Buy Juniper Berry online The development of second- and third-generation agents has provided hematologists and oncologists with additional salvage treatment options for nonresponding patients and has also given clinicians the ability to match agents with patient characteristics in order to minimize potential toxicity. Clinical trials may not be representative of real-world settings However, most information about TKI therapy in CML is derived from large clinical trials that include restrictive entry criteria with rigorous monitoring and treatment algorithms. Thus, the results of clinical trials may not be representative of treatment patterns or outcomes in real-world settings. In the study reported at the European Hematology Association meeting, about one third of patients were more than 60 years of age, and most had significant pre-existing morbid conditions. http://webmd-help.blogspot.com Many of these patients would not have been eligible for clinical trials. The analysis found that imatinib was the most commonly used first-line agent in the community setting, dasatinib and nilotinib were the most commonly used second-line agents, and bosutinib and ponatinib were the most commonly used third-line agents. Also, bosutinib-treated patients were the oldest (with a median age of 56 years) and had the most co-morbid conditions (with a mean Charlson Co-Morbidity Index score of 6.2). Bosutinib-treated patients were more likely to have a history of vascular occlusive conditions, kidney diseases and pleural effusion at baseline. However, bosutinib-treated patients had the lowest rates of serious TEAEs, except for diarrhea. In particular, serious cardiovascular events were significantly less common in the bosutinib group. For example, only 1% of them developed treatment-emergent congestive heart failure versus 6% of ponatinib patients. Fluid retention occurred in 3% of bosutinib patients compared to 10% of ponatinib, 6% of dasatinib and 5% of nilotinib patients. "Thus for the patient with a significant cardiac history, bosutinib may be a good therapeutic option," Dr. Goldberg said. Only 15% of the bosutinib group discontinued treatment because of serious TEAEs versus 19-29% with the other TKIs. "We were comforted to find that the overall toxicity profiles of TKIs in CML patients in the real-world setting mirror those seen in clinical trials," Dr. Goldberg added. He emphasized that the findings need to be confirmed in multivariate analyses and larger sample sizes. Written by Jill Stein

Quintiles et Quest Diagnostics lancent Q2 Solutions

RESEARCH TRIANGLE PARK, Caroline du Nord et MADISON, New Jersey--(BUSINESS WIRE)--Quintiles et Quest Diagnostics ont annonc e aujourd hui le lancement de Q2 Solutions, leur nouvelle organisation conjointe de services d essais cliniques en laboratoire. Trial Packs () with free prescription Q2 Solutions r eunit les op erations d essais cliniques en laboratoire des deux soci et es m`eres afin de fournir aux clients biopharmaceutiques les capacit es diverses et services de bout-en-bout n ecessaires au sein du secteur biopharmaceutique `a l evolution rapide. Colofac (Mebeverine) Le lancement aujourd hui de Q2 Solutions r esulte de la cl^oture de la transaction autour d une co-entreprise globale de services d essais cliniques en laboratoire pr ec edemment annonc ee. Q2 Solutions b en eficie d une position forte en tant que deuxi`eme plus grande soci et e centrale de services en laboratoire au monde, et fournit ses services aux clients issus de tous les segments de l industrie biopharmaceutique – groupe comprenant l ensemble des 20 plus grandes soci et es biopharmaceutiques. Jelly Pack-30 () with free prescription Si Q2 Solutions avait et e une entreprise ind ependante en 2014, l organisation aurait g en er e un chiffre d affaires annuel de pr`es de 575 millions USD. Quintiles, le plus grand fournisseur au monde en mati`ere de services de d eveloppement de produits et de services de soins de sant e int egr es, d etient 60 % et Quest Diagnostics, le leader mondial en services d informations de diagnostic, d etient 40 % des deux entit es juridiques distinctes qui composent Q2 Solutions. « Q2 Solutions tire parti des forces compl ementaires, de l expertise et de l ampleur de deux leaders du secteur », a d eclar e Tom Pike, pr esident-directeur g en eral de Quintiles. About Capoten without Rx « Cette nouvelle organisation s appuie sur les fondations solides de ses soci et es m`eres, et fournit aux clients un acc`es `a un partenaire innovant, progressiste et r eactif, qui offre l accent sur la qualit e, l exp erience internationale et l expertise m edicale approfondie indispensables au d eveloppement de m edicaments. » « Les services cliniques en laboratoire constituent des el ements essentiels pour faire progresser la g enomique, la m edecine de pr ecision et le d eveloppement de m edicaments. Buy Himcolin () without Rx Q2 Solutions est bien positionn ee pour r ealiser des avanc ees significatives dans ces domaines, qui b en eficieront `a la fois aux clients biopharmaceutiques et aux patients », a d eclar e Steve Rusckowski, pr esident et chef de la direction chez Quest Diagnostics. Buy Hair Loss online « Cette transaction est conforme `a la strat egie en quatre points de Quest, dans la mesure o`u elle nous permet de maximiser la valeur de nos actifs en mati`ere d essais cliniques d une mani`ere rentable, tout en recentrant nos efforts sur notre activit e strat egique de services d information de diagnostic. » Les deux soci et es m`eres ont egalement d ebut e une p eriode de collaboration exclusive visant `a explorer la mani`ere dont elles pourraient utiliser leurs actifs de donn ees afin d optimiser certains domaines tels que le recrutement et la r etention des patients aux essais cliniques, la conception d essais cliniques, ainsi que le d eveloppement et la commercialisation de tests de diagnostic compagnon. L equipe de direction exp eriment ee de Q2 Solutions se compose de leaders eprouv es issus de Quintiles et Quest Diagnostics. http://pharmaceuticaljournal.wordpress.com Costa Panagos, pr esident-directeur g en eral de la soci et e, occupait r ecemment le poste de vice-pr esident principal et de responsable mondial des divisions Laboratoires mondiaux et Services de s ecurit e cardiaque chez Quintiles. « Aujourd hui se franchit une etape importante aussi bien pour Q2 Solutions, que pour l industrie biopharmaceutique au sens large que nous desservons », a d eclar e Panagos. « Q2 Solutions fournit aux clients une expertise scientifique leader du secteur, un large r eseau international de laboratoires, et une d etermination constante `a assurer une qualit e sup erieure pour atteindre de meilleurs r esultats th erapeutiques. Ces el ements s inscrivent au coeur de la promesse de Q2 Solutions qui consiste `a aider les clients `a am eliorer la sant e humaine gr^ace `a une innovation capable de transformer la science et les donn ees en d ecouvertes m edicales exploitables. » Pour en savoir plus sur Q2 Solutions, rendez-vous sur .Q2LabSolutions.com. `A propos de Quintiles Quintiles (NYSE : Q) aide les soci et es biopharmaceutiques et d autres soci et es de soins de sant e `a am eliorer leurs chances de r eussite en connectant les id ees de notre vaste expertise scientifique, th erapeutique et analytique `a une livraison sup erieure pour de meilleurs r esultats. Des services-conseils aux op erations, Quintiles est le plus grand fournisseur au monde en mati`ere de services de d eveloppement de produits et de services de soins de sant e int egr es, avec notamment des solutions commerciales et observationnelles. Avec des op erations dans pr`es de 100 pays, Quintiles est un membre du classement FORTUNE 500 et a et e nomm ee dans la liste FORTUNE des « Soci et es les plus admir ees dans le monde ». Pour en savoir plus, pri`ere de visiter .quintiles.com. `A propos de Quest Diagnostics Quest Diagnostics (NYSE : DGX) incite les individus `a entreprendre des actions afin d am eliorer les r esultats de sant e. Etay ees par la base de donn ees de r esultats cliniques en laboratoire la plus importante au monde, nos informations de diagnostic r ev`elent de nouvelles voies permettant d identifier et de soigner les maladies, d encourager les comportements sains et d am eliorer la gestion des soins de sant e. Quest dessert chaque ann ee un patient adulte am ericain sur trois, ainsi que la moiti e des m edecins et h^opitaux des  Etats-Unis. Nos 45 000 employ es sont conscients que, plac ees en de bonnes mains et dans un contexte adapt e, nos informations de diagnostic sont susceptibles d encourager des actions qui transformeront des vies. Quest Diagnostics est membre du FORTUNE 500, et figure dans la liste des « Soci et es les plus admir ees au monde » de FORTUNE. .QuestDiagnostics.com D eclarations pr evisionnelles Les d eclarations de ce communiqu e de presse qui ne sont pas des faits historiques, y compris celles concernant la transaction de la coentreprise, peuvent contenir des « d eclarations pr evisionnelles » au sens de la Section 27A de la loi Securities Act de 1933 et de la section 21E de la loi Securities Exchange Act de 1934. Ces d eclarations pr evisionnelles refl`etent, entre autres, les attentes actuelles et les r esultats d’exploitation anticip es de Quintiles et Quest Diagnostics, el ements qui sont tous assujettis `a des risques connus et inconnus, `a des incertitudes, et `a d’autres facteurs pouvant faire varier sensiblement les r esultats r eels, la performance, les r ealisations, les tendances du march e, ou les r esultats du secteur de ceux exprim es ou sous-entendus par de telles d eclarations pr evisionnelles. Ainsi, les lecteurs sont pri es de ne pas se fier outre mesure `a ces d eclarations pr evisionnelles qui sont uniquement valides `a la date `a laquelle elles ont et e enonc ees. Sans limiter la port ee de ce qui pr ec`ede, les mots, tels que « anticipe », « croit », « estime », « s’attend `a », « a l’intention de », « peut », « pr evoit », « projette », « devrait », « cible », l’usage du futur et leur forme n egative, ainsi que les mots et expressions analogues sont destin es `a identifier des d eclarations pr evisionnelles. Ces d eclarations sont assujetties `a des risques, incertitudes et hypoth`eses, y compris, sans limitation, la capacit e de compl eter, d’int egrer et de r ealiser les objectifs pr evus `a l egard de Q2 Solutions, de d evelopper de nouvelles technologies, l environnement concurrentiel, les poursuites juridiques ou les actions priv ees, les r esultats d efavorables des enqu^etes gouvernementales en cours ou futures, la capacit e d attirer et de conserver les employ es cl es de la nouvelle soci et e ; ainsi que d autres facteurs d ecrits dans les documents que Quintiles et Quest Diagnostics d eposent r eguli`erement aupr`es de la SEC, y compris les facteurs d ecrits dans la section intitul ee « Risk Factors » du (i) rapport annuel 2014 de Quintiles d epos e aupr`es de la SEC sur formulaire 10-K le 12 f evrier 2015, et du(ii) rapport annuel 2014 de Quest Diagnostics d epos e aupr`es de la SEC sur formulaire 10-K le 24 f evrier 2015. Ces facteurs peuvent ^etre mis `a jour de temps `a autre dans les documents que les soci et es respectives d eposent r eguli`erement aupr`es de la SEC et qui sont accessibles sur le site Web de la SEC `a l adresse .sec.gov. Ces facteurs ne doivent pas ^etre interpr et es comme etant exhaustifs et doivent ^etre lus conjointement avec les autres avertissements qui sont inclus dans ce communiqu e de presse, ainsi que dans les documents d epos es par Quintiles et Quest Diagnostics aupr`es de la SEC. Sauf en cas d’obligation l egale, Quintiles et Quest Diagnostics d eclinent toute obligation d’actualiser ces d eclarations pr evisionnelles pour refl eter des r esultats r eels ou des changements dans les facteurs affectant ces informations `a caract`ere pr evisionnel. Cliquez ici pour vous abonner aux alertes sur mobile concernant Quintiles. Le texte du communiqu e issu d’une traduction ne doit d’aucune mani`ere ^etre consid er e comme officiel. La seule version du communiqu e qui fasse foi est celle du communiqu e dans sa langue d’origine. La traduction devra toujours ^etre confront ee au texte source, qui fera jurisprudence.

Benefits of extracurricular sports extend into the classroom

Extracurricular sports have long been promoted as a way of keeping children healthy, but new research suggests they could also provide benefits in the classroom, helping children remain engaged and disciplined. The study suggests an association between physical activity and self-regulation from kindergarten to fourth grade. The study, published in the American Journal of Health Promotion, found that children who regularly participated in structured sports were better at following instructions and remaining focused in the classroom than their peers by the time they reached fourth grade. "There is something specific to the sporting environment - perhaps the unique sense of belonging to a team, a special group with a common goal - that appears to help kids understand the importance of respecting the rules and honoring responsibilities," explains study author Linda Pagani of the University of Montreal, Canada. For the study, Pagani and colleagues analyzed data obtained from the Quebec Longitudinal Study on Child Development on 2,694 children born between 1997 and 1998. Trial Packs () with free prescription She explains the aims of the study: "Our goal was to answer two questions: firstly, does participation in extracurricular activities in kindergarten predict fourth-grade self-discipline, and secondly, do kindergarten self-discipline characteristics predict fourth-grade participation in sports?" Information was provided by both the teachers and parents of children in kindergarten, detailing the behavior of the children while in school and at home. Colofac (Mebeverine) Four years later, when the children had reached fourth grade, the information-gathering exercise was repeated. Once they had obtained the data, the researchers took into account other factors that could have influenced their findings such as the children s physical fitness, parental education levels and how well the family unit functioned. The researchers found that children who participated in structured activities such as sports while at kindergarten were more likely to be involved in sports by the time they reached fourth grade. Jelly Pack-30 () with free prescription In contrast, participating in unstructured activities had no impact on the child s future. Extracurricular sports could prevent kids from being left behind "Across the board, we found that children who had better behavior in the kindergarten class were more likely to be involved in sport by age 10," reports Pagani. About Capoten without Rx "Nonetheless, we found that those children who were specifically involved in team sports at kindergarten scored higher in self-regulation by the time they reached fourth grade." According to the researchers, sporting activities and attention skills are intrinsically linked, and school planning can use this association to the benefit of pupils. Buy Himcolin () without Rx Additionally, pupils deemed to be at risk of not getting enough exercise could be targeted to improve both obesity and school drop-out rates. "Programs to help parents develop their child s self-regulation skills and the availability of extracurricular sports programs as early as kindergarten could help decrease the risk of kids being left behind," Pagani suggests. The researchers hope that their findings can be of use to policymakers outside of schools as well, leading to improved access to parks and playgrounds for children and their families and to promoting active schools and communities as a whole. According to a report released this past December by the US Census Bureau, there are a large number of children that do not currently participate in extracurricular activities. Buy Hair Loss online Although children were found to be more likely to participate in sports than other activities, only 57% of children aged 6-17 participate in at least one after-school extracurricular activity. The report identified household structure as a factor that influenced how likely a child was to be involved in extracurricular activities. http://pharmaceuticaljournal.wordpress.com Children whose parents were married and lived together were more likely to participate than children living with cohabiting parents or a single parent. Recently, Medical News Today reported on a study finding that when teenagers exercise like young children - in short bursts of intense activity - their health outcomes are improved. Written by James McIntosh

Benefits of extracurricular sports extend into the classroom

Extracurricular sports have long been promoted as a way of keeping children healthy, but new research suggests they could also provide benefits in the classroom, helping children remain engaged and disciplined. The study suggests an association between physical activity and self-regulation from kindergarten to fourth grade. The study, published in the American Journal of Health Promotion, found that children who regularly participated in structured sports were better at following instructions and remaining focused in the classroom than their peers by the time they reached fourth grade. "There is something specific to the sporting environment - perhaps the unique sense of belonging to a team, a special group with a common goal - that appears to help kids understand the importance of respecting the rules and honoring responsibilities," explains study author Linda Pagani of the University of Montreal, Canada. For the study, Pagani and colleagues analyzed data obtained from the Quebec Longitudinal Study on Child Development on 2,694 children born between 1997 and 1998. Trial Packs () with free prescription She explains the aims of the study: "Our goal was to answer two questions: firstly, does participation in extracurricular activities in kindergarten predict fourth-grade self-discipline, and secondly, do kindergarten self-discipline characteristics predict fourth-grade participation in sports?" Information was provided by both the teachers and parents of children in kindergarten, detailing the behavior of the children while in school and at home. Colofac (Mebeverine) Four years later, when the children had reached fourth grade, the information-gathering exercise was repeated. Once they had obtained the data, the researchers took into account other factors that could have influenced their findings such as the children s physical fitness, parental education levels and how well the family unit functioned. The researchers found that children who participated in structured activities such as sports while at kindergarten were more likely to be involved in sports by the time they reached fourth grade. Jelly Pack-30 () with free prescription In contrast, participating in unstructured activities had no impact on the child s future. Extracurricular sports could prevent kids from being left behind "Across the board, we found that children who had better behavior in the kindergarten class were more likely to be involved in sport by age 10," reports Pagani. About Capoten without Rx "Nonetheless, we found that those children who were specifically involved in team sports at kindergarten scored higher in self-regulation by the time they reached fourth grade." According to the researchers, sporting activities and attention skills are intrinsically linked, and school planning can use this association to the benefit of pupils. Buy Himcolin () without Rx Additionally, pupils deemed to be at risk of not getting enough exercise could be targeted to improve both obesity and school drop-out rates. "Programs to help parents develop their child s self-regulation skills and the availability of extracurricular sports programs as early as kindergarten could help decrease the risk of kids being left behind," Pagani suggests. The researchers hope that their findings can be of use to policymakers outside of schools as well, leading to improved access to parks and playgrounds for children and their families and to promoting active schools and communities as a whole. According to a report released this past December by the US Census Bureau, there are a large number of children that do not currently participate in extracurricular activities. Buy Hair Loss online Although children were found to be more likely to participate in sports than other activities, only 57% of children aged 6-17 participate in at least one after-school extracurricular activity. The report identified household structure as a factor that influenced how likely a child was to be involved in extracurricular activities. http://pharmaceuticaljournal.wordpress.com Children whose parents were married and lived together were more likely to participate than children living with cohabiting parents or a single parent. Recently, Medical News Today reported on a study finding that when teenagers exercise like young children - in short bursts of intense activity - their health outcomes are improved. Written by James McIntosh